



Dear Provider,

Specialty therapies can be complex, and complete information is essential to help ensure timely access to care.

The following prescriber order form is designed to capture the necessary clinical and patient information the dispensing pharmacy requires to begin the applicable prescribed therapy.

If your patient has elected to use Option Care Health, please fax completed form and required clinical documentation to **713-983-4647**.

Sincerely,
Option Care Health

TEPEZZA® (TEPROTUMUMAB-TRBW) PRESCRIBER ORDER FORM					
Patient Name:			Date of Birth:		Gender:
Address:					
Phone:		Height:		☐ inches ☐ cm	Weight: ☐ lbs ☐ kg
Clinical Information					
Primary Diagnosis Description: Thyroid eye disease				ICD-10 Code: E05.00	
Tepezza® (Teprotumumab-trbw) Prescription					
Tepezza® (Teprotumumab-trbw) Option Care Health to initiate services beginning with Dose No. _____ as indicated below: Dose 1: Infuse 10 mg/kg IV over 90 minutes, then 3 weeks later... Dose 2: Infuse 20 mg/kg IV over 90 minutes, then 3 weeks later... Dose 3 through 8: Infuse 20 mg/kg IV over 60 to 90 minutes (as tolerated by patient) every 3 weeks x 6 doses. Dispense quantity sufficient of Tepezza® 500 mg single dose vials for each dose. Withdraw calculated dose from vial and discard any unused vial contents. Prescriber to assess hearing before, during, and after treatment.					
Ancillary Orders					
Anaphylaxis Kit If this is a 1st infusion dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose? ☐ Yes ☐ No Dosage: ☐ Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SUBQ or IM x 1; repeat x 1 in 5 to 15 min PRN. ☐ Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg – 25mg max dose) IV or IM; repeat x 1 in 15 min PRN no improvement. ☐ 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis.					
Pre-Medication Orders ☐ Acetaminophen 650 mg PO 30 min before infusion. Patient may decline. ☐ Diphenhydramine 25 mg PO 30 min before infusion. Patient may decline. ☐ Other: _____					
IV Flush Orders ☐ <u>Peripheral:</u> 0.9% Sodium Chloride 3 to 5 mL pre-/post-use. ☐ <u>Implanted Port:</u> 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.					
Lab Orders ☐ No labs ordered at this time. ☐ Other: _____ Skilled nurse to assess and administer and/or teach self-administration where appropriate via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year. If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.					
<i>I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.</i>					
Prescriber Signature: _____				Date: _____	
Prescriber Information					
Prescriber Name:			Phone:		Fax:
Address:			NPI:		
City, State:		Zip:		Office Contact:	
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.					